A Phase 1 Clinical Trial to Evaluate the Safety and DDI o... | NCT07343245

Studies
A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDs

NCT07343245

Sponsor

Daewon Pharmaceutical Co., Ltd.

Status

Recruiting

Last Update Posted

Jan 15, 2026Actual

Enrollment

150Estimated

Phase

Phase 1

Conditions

Healthy Adult

Interventions

DW4421
DW4421-N1
DW4421-N2
DW4421-N3

Countries

South Korea

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Jan 2026

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Dec 1, 2025Actual

Primary Completion Date

Feb 22, 2026Estimated

Completion Date

Jun 17, 2026Estimated

First Submitted Date

Dec 22, 2025

First Submission Date that Met QC Criteria

Jan 6, 2026

First Posted Date

Jan 15, 2026Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 6, 2026

Last Update Posted Date

Jan 15, 2026Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

150Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Intervention Names
Cohort 1, A	Experimental	Drug: DW4421 Drug: DW4421-N1
Cohort 1, B	Experimental	Drug: DW4421 Drug: DW4421-N1
Cohort 2, C	Experimental	Drug: DW4421 Drug: DW4421-N2
Cohort 2, D	Experimental	Drug: DW4421 Drug: DW4421-N2
Cohort 3, E	Experimental	Drug: DW4421 Drug: DW4421-N3
Cohort 3, F	Experimental	Drug: DW4421 Drug: DW4421-N3

Interventions

Name	Type	Description	Arm Group Labels	Other Names
DW4421	Drug	QD	Cohort 1, A Cohort 1, B Cohort 2, C Cohort 2, D Cohort 3, E Cohort 3, F

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Cmax,ss		Baseline to Day 13 or Day 15
AUCτ,ss		Baseline to Day 13 or Day 15

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Healthy adult aged 19 to 50 (inclusive) years, at the time of screening.
Subjects weighing between 50 kg and 90 kg with BMI between 18 and 27 kg/m2 (inclusive) at screening visit.

Exclusion Criteria:

Those who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

19 Years

Maximum Age

50 Years

Standard Ages

Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Chungbuk National University Hospital	Recruiting	Cheongju-si			South Korea